Synonyms: PTC-299 | PTC299
Compound class:
Synthetic organic
Comment: Emvododstat (PTC299) is an orally bioavailable inhibitor of dihydroorotate dehydrogenase (DHODH) that was developed by PTC Therapeutics [1] for anti-cancer potential. It inhibits de novo pyrimidine nucleotide (UMP) biosynthesis and exhibits broad activity against leukemia in vitro and in vivo.
SARS-CoV-2: Emvododstat inhibits replication of SARS-CoV-2 in vitro (EC50 2.0-31.6 nM) and other RNA viruses [2]. It blocks production of inflammatory cytokines in infected cell cultures. |
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
(4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate |
International Nonproprietary Names | |
INN number | INN |
11614 | emvododstat |
Synonyms |
PTC-299 | PTC299 |
Database Links | |
CAS Registry No. | 1256565-36-2 (source: WHO INN record) |
GtoPdb PubChem SID | 440816790 |
PubChem CID | 49787172 |
Search Google for chemical match using the InChIKey | SRSHBZRURUNOSM-DEOSSOPVSA-N |
Search Google for chemicals with the same backbone | SRSHBZRURUNOSM |
Search PubMed clinical trials | emvododstat |
Search PubMed titles | emvododstat |
Search PubMed titles/abstracts | emvododstat |
UniChem Compound Search for chemical match using the InChIKey | SRSHBZRURUNOSM-DEOSSOPVSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | SRSHBZRURUNOSM-DEOSSOPVSA-N |